oxygenta pharmaceutical will hold its 33rd Annual General Meeting on August 21, 2026, to approve material related party transactions (RPTs) worth ₹450 crore with its holding company, Virupaksha Organics Limited (VOL), alongside the regularization of key board appointments. The approvals are essential for maintaining operational synergies and financial support structures within the promoter group during FY 2026-27. The meeting underscores the company’s reliance on VOL for both commercial trade and liquidity, particularly as Oxygenta reported a net loss of ₹1,757.17 lakhs for FY 2025-26 against revenue of ₹11,298.19 lakhs.

The Board of Directors seeks shareholder approval for two primary categories of transactions with VOL, which holds a 56.50% stake in the company. These include commercial transactions for the sale and purchase of goods, capped at ₹250 crore, and financial arrangements involving inter-corporate borrowings and guarantees, capped at ₹200 crore. The resolutions require compliance with Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates shareholder approval for material RPTs exceeding specified thresholds. All transactions are intended to be conducted at arm’s length.

Related Party Transaction Details

The proposed transactions are structured to support the company’s operational continuity and liquidity needs. The aggregate value for commercial transactions is capped at ₹250 crore, while financial facilities are capped at ₹200 crore. The inter-corporate borrowings carry an interest rate of 9% per annum with a tenure of three years. The funds are designated for repaying unsecured loans and clearing outstanding vendor payments. VOL has provided corporate guarantees for these facilities, mitigating risk for the lenders.

Board Appointments and Governance

Shareholders will vote on the regularisation of two additional directors appointed by the Board on May 23, 2026. Amireddy Venkatesu Reddy is proposed for appointment as Whole-Time Director for a term of three years, effective May 23, 2026. His remuneration is set within a pay scale of ₹6,00,000 to ₹8,00,000 per month, subject to the limits prescribed under Schedule V of the Companies Act, 2013. Venkatesu Reddy brings over 26 years of experience in the pharmaceutical industry, including prior association with VOL.

Janardhana Reddy Yeddula is proposed for appointment as an Independent Director for a five-year term, also effective May 23, 2026. He holds a bachelor’s degree in commerce and a diploma in labour laws. Yeddula currently serves as an Independent Director at Virupaksha Organics Limited and Sigachi Industries Limited. His appointment aims to strengthen governance oversight, particularly given the recent change in control following VOL’s acquisition. The AGM also addresses the reappointment of Balasubba Reddy Mamilla, who retires by rotation and continues as Whole-Time Director.

Financial Context and Going Concern

Statutory Auditors M/s. A.M. Reddy & D.R. Reddy have issued an unmodified opinion on the financial statements. However, the auditor’s report highlights a material uncertainty related to going concern due to accumulated losses and negative equity of ₹4,268.68 lakhs. The Board cites continued financial support from VOL and a restructuring plan as mitigating factors. Cost Auditor M/s. PCR & Associates has been appointed for FY 2026-27 with a remuneration of ₹75,000 per annum, pending ratification. The company’s debt-to-equity ratio stands at -2.57 times, reflecting the negative net worth position.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE102E01018/5524a56c-16b5-4c3b-bd6f-468974c8d60c.pdf

Oxygenta Pharmaceutical Limited reported a significant improvement in its financial health for the first quarter of FY27, with net losses narrowing by 66% year-on-year to ₹2.10 crore. The Hyderabad-based pharmaceutical manufacturer achieved this turnaround primarily through a robust 144% surge in revenue from operations, which climbed to ₹36.99 crore from ₹15.13 crore in the corresponding period of the previous year. This top-line growth signals strengthening demand and operational scale, although the company continues to navigate margin pressures that have kept it in the red for the quarter.

The Board of Directors approved the unaudited financial results during a meeting held on July 27, 2026, at the company’s corporate office in Hyderabad. Statutory auditors A.M Reddy & D.R Reddy conducted the limited review in accordance with Standard on Review Engagements (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In addition to approving the results, the Board appointed M/s. PCR & Associates as Cost Auditors for FY27, subject to shareholder ratification, and scheduled the Annual General Meeting for August 21, 2026.

Financial Performance Highlights

Total revenue for the quarter reached ₹37.02 crore, up from ₹15.30 crore in Q1FY26. However, total expenses also expanded significantly to ₹39.53 crore from ₹23.44 crore, reflecting higher production volumes and increased financing costs. Cost of materials consumed rose to ₹23.40 crore, while finance costs nearly quadrupled to ₹2.46 crore from ₹0.63 crore. This increase in interest burden is partly attributed to new borrowings under government support schemes, specifically ₹3.99 crore availed under the Emergency Credit Line Guarantee Scheme (ECLGS).

Despite the revenue growth, the company recorded an operational loss before tax of ₹2.51 crore, compared to ₹8.15 crore in Q1FY26. A deferred tax credit of ₹0.40 crore helped reduce the final net loss. Earnings per share stood at a loss of ₹0.57, an improvement from the loss of ₹1.65 in the prior year period.

What the Numbers Show

The divergence between revenue growth and expense inflation highlights ongoing margin pressure. While revenue more than doubled year-on-year, total expenses grew by 69%, indicating that input costs and financing charges are absorbing much of the top-line gain. The sharp rise in finance costs suggests increased leverage, corroborated by the disclosure of ₹3.99 crore in ECLGS assistance. While this injection supports liquidity, it adds to the interest burden, potentially delaying the path to operational profitability. Additionally, the company disclosed gaps in identifying MSME creditors and has requested self-declarations from suppliers to improve compliance accuracy.

Corporate Governance Updates

Beyond financials, the Board reconstituted the POSH Committee effective July 27, 2026. Ms. Kurapati Divya serves as Presiding Officer, supported by internal members Ms. Kuchipudi Jyothi, Ms. B. Rajitha, Ms. S. Chandraleka, and Ms. Yempally Sindhu, along with external member Ms. D. Rajeswari. These appointments ensure compliance with workplace safety regulations as the company scales operations.